1 BTC
=
- USD
Agenus Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Agenus Inc.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Market Statistics
Trading Metrics
How to Buy AGEN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy AGEN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesA comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.
Agenus reported Q3 2024 results highlighting groundbreaking clinical progress with BOT/BAL immunotherapy in hard-to-treat cancers, particularly microsatellite-stable colorectal cancer. However, the company faces significant financial constraints with only $44.8 million in cash at quarter-end. Management is pursuing cost reductions, real estate asset monetization ($45M+ in properties), and strategic partnerships to fund Phase 3 trials and extend runway. Multiple data presentations from neoadjuvant trials are expected in early 2025.
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
The U.S. pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is expected to grow from $36.77 billion in 2024 to $68.57 billion by 2034, driven by increased demand for specialized pharmaceutical services, technological advancements, and growing needs in oncology and complex drug development.